Pharmaceuticals giant GlaxoSmithKline announced on Friday afternoon that it has completed, along with partner Theravance, the phase III programme of a 52-week safety study for its UMEC/VI medicine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
The 6,000-patient study, along with other recently completed studies, "supports GSK's plans to commence global regulatory submissions for UMEC/VI from the end of 2012," the firm said.
UMEC/VI is one of several late-stage assets in Glaxo's respiratory development portfolio which have not yet been approved anywhere in the world.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Shares were trading 0.69% higher at 1,461p before the close.
BC
-
Crypto ETN warning: why adding them to your ISA could be riskyCrypto investors could be exposed to short-term market volatility thanks to HMRC rules if they buy cETNs into a stocks and shares ISA
-
Radical reforms to state pension age and guaranteed payouts proposedThe state pension age should rise by one year every decade “for the foreseeable future” to make the payments more affordable, former pensions minister Steve Webb has suggested
